On the 24th of August 2001, a group of business and licensing executives united in Basel and founded the Swiss Pharma Licensing Group. The first Board defined objectives, recruited members and set up the foundation for today’s association.
Special Swiss HLG offer!
* €100 discount for the first 10 Swiss HLG Members that register – discount code: 10SwissHLG
* €150 discount for the first 10 Swiss HLG Start-Up Members that register – discount code 10SUSwissHLG
**The codes should be entered in the ‘Submit Promotion Code’ box on the payments page
|Swiss HLG, member of the European Pharma Licensing Council (EPLC), invites you to join the International Pharma Licensing Symposium in Paris |
Without question we live in interesting times, the 15th IPLS has been
designed to explore some of the more disruptive influences and opportunities in the life science industry today.
Two days of informative presentations from industry leading speakers, peer to peer networking, one-to-one meeting opportunities and continuous personal development, all in the world’s most popular and dynamic city, Paris.
Conference Programme Includes:
Contemporary Trends in Pharma Business Development
Evolution of Business Development Teams
The Continuum of Ageing & Age-Related Diseases
Ageing Opportunities in Pharmaceuticals
New Therapeutic Advances
And much more, including 7 hours of dedicated one-to-one partnering
Full Programme & Event Website
REGISTER ONLINE NOW
|XV International Pharma Licensing Symposium|
Pullman Hotel Paris Centre – Bercy
Wednesday 18th to Friday 20th September 2019
Who Should Attend? Business Development Professionals, Managing
Directors, General Managers, Business Owners, Investors, Advisors,
Financial, Marketing& Regulatory Executives
REGISTER ONLINE NOW
The joint summer conference between the Italian and Swiss Healthcare Licensing Groups took place on the 6th – 7th June in Milan. Over 80 attendees enjoyed the cutting-edge conference on various topics including, The current Italian and Swiss pharmaceutical markets evolution, Partnering in the field of advanced therapies, analysis of 2018 and beginning of 2019 BD&L deals with an interesting discussion about the trends. The artificial intelligence and its impact on BD&L, Business intelligence as a tool to evaluate new BD&L opportunities, Health technology and its impact on the value chain and Trends in the orphan drugs regulations and pricing and pricing of breakthrough therapies in a challenging healthcare system.Read More…
The 2019 Swiss Healthcare Licensing Group (HLG) Winter Conference focused on the topic “Capture Deal Value – When and How?”
The pharmaceutical industry is facing increasing challenges to cope with the quickly changing world economy. The requirements in healthcare are becoming ever more demanding considering the higher standard of data, financial investments and time, let alone governments` cost-containment measures getting more restrictive.
Both new and innovative molecules in the pipeline and growing access of patients to drug treatment especially in emerging markets are at the same time positive signals though. It seems that the pharmaceutical industry still finds room for creative ways to explore and implement new business models keeping pace with current changes in the healthcare environment.
Over three days, nearly 100 delegates from Switzerland, Europe, the US and Asia gathered in the Gruyère region to explore current and future innovative ways when and how to capture maximum deal value.
Conference Director, Ragip Ziyal with the active support of the entire Swiss HLG Board, gathered a global forum of high caliber speakers not only from the healthcare and consumer industry but also governmental initiatives to capture the maximum value for assets in the best manner and at the right time by (I) learning how synergies may be exploited for example during M&A transactions, (II) discussing the need for strategic access to new technologies and (III) looking at new players such as new public and public-private funding schemes as well as patient and non-profit organizations to support R&D funding.Read More…